On April 22, 2024, regarding the case Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc. et al., case number 23-768, the US Supreme Court denied Vanda’s request to review an appeals court decision that invalidated several patents for Hetlioz (tasimelteon). Teva is represented by John Christopher RozendaalDeirdre Wells, and William Milliken from Sterne Kessler Goldstein & Fox.